TNMG:NASDAQTNL Mediagene Analysis
Data as of 2026-08-31 - not real-time
$0.49
Latest Price
9/10Risk
Risk Level: High
Executive Summary
TNL Mediagene trades at $0.4904, with its moving averages tangled rather than clearly stacked — a neutral trend structure. Across the trailing 30 sessions it gained 50.9%. Relative strength is 53.1 — neutral — and the MACD signal is bullish. Recent trading has carved out support near $0.3700 and resistance around $0.8910.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 2754.8% above the current quote. Revenue is growing at 5.7% on a -167.9% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 166.8%, a beta of 2.38 and a maximum drawdown of 97.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 2754.8% above the current quote. Revenue is growing at 5.7% on a -167.9% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 166.8%, a beta of 2.38 and a maximum drawdown of 97.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 2.07
- MACD momentum is positive
- 30-day price change of +50.9%
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 2.07
- Analyst targets imply +2754.8% versus the current price
- 30-day volatility of 166.8%
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Negative profit margin of -167.9%
- Analyst targets imply +2754.8% versus the current price
- Negative return on equity of -164.6%
Key Metrics & Analysis
Financial Health
Revenue Growth5.70%
Profit Margin-167.90%
P/E Ratio-3.5
ROE-164.59%
ROA-31.70%
Debt/Equity58.06
P/B Ratio0.0
Op. Cash Flow$-11133360
Free Cash Flow$-24020994
Industry P/E16.1
Technical Analysis
TrendNeutral
RSI53.1
Support$0.37
Resistance$0.89
MA 20$0.47
MA 50$0.46
MA 200$2.07
MACDBullish
VolumeDecreasing
Fear & Greed Index94.79
Valuation
Target Price$14.00
Upside/Downside2754.81%
GradeUndervalued
TypeBlend
Risk Assessment
Beta2.38
Volatility166.83%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.